Also trades as: 0H8T.L (LSE) · $vol 0M
ACRS NASDAQ
Aclaris Therapeutics, Inc.
1W: -14.8%
1M: -29.0%
3M: -20.0%
YTD: +52.4%
1Y: +134.8%
3Y: -34.1%
5Y: -75.7%
$4.39
-0.02 (-0.45%)
Weekly Expected Move ±11.7%
$3
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-05-20
Earliest Filing
2024-11-18
Latest Filing
partner: 7
investor: 2
Counterparties (Filed by ACRS)
9 relationshipsCompanies named in ACRS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Biosion, Inc. | — | partner | Exclusive license and collaboration partner for BSI-045B and BSI-502 | 2024-11-18 | View |
| Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. | — | partner | Licensee of Licensed Products outside the Territory | 2024-11-18 | View |
| OCM IP Healthcare Portfolio LP | — | investor | Acquired a portion of future royalty payments and remaining milestone payments from Aclaris Therapeutics, Inc. related t | 2024-07-16 | View |
| OMERS | — | investor | Parent investment vehicle of OCM IP Healthcare Portfolio LP that acquired royalties from Aclaris Therapeutics, Inc. | 2024-07-16 | View |
| Eli Lilly and Company | LLY | partner | Holds the existing license agreement with Aclaris Therapeutics, Inc. for OLUMIANT, from whom royalties are being purchas | 2024-07-16 | View |
| CBCC – Lee Road Acquisitions, LLC | — | partner | Landlord for corporate headquarters office lease | 2023-06-01 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for the Company's common stock offering | 2023-02-23 | View |
| SVB Leerink LLC | — | partner | Sales agent for the at-the-market offering of common stock | 2021-05-20 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for the at-the-market offering of common stock | 2021-05-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-08-06 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-28 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-11 | Regulation FD Disclosure | View | |
| 2026-03-10 | Regulation FD Disclosure | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-06 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-30 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-05 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR